MARKET

CERS

CERS

Cerus
NASDAQ
1.970
-0.050
-2.48%
Opening 09:51 11/09 EST
OPEN
2.010
PREV CLOSE
2.020
HIGH
2.020
LOW
1.910
VOLUME
404.73K
TURNOVER
--
52 WEEK HIGH
3.470
52 WEEK LOW
1.380
MARKET CAP
397.85M
P/E (TTM)
-52.9570
1D
5D
1M
3M
1Y
5Y
1D
TD Cowen Keeps Their Buy Rating on Cerus (CERS)
TipRanks · 6d ago
Adeia Posts Downbeat Q3 Earnings, Joins Bioventus, Apple And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Benzinga · 6d ago
Cerus Buy Rating Maintained at $4 on Positive Phase 3 RBC Results and Strong Q3 Execution
TipRanks · 6d ago
Why Aehr Test Systems Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Benzinga · 6d ago
Cerus Q3 2026 Earnings Call Transcript
Benzinga · 6d ago
Cerus files $150M mixed securities shelf
TipRanks · 6d ago
Cerus Files Prospectus To Offer And Sell Up To $150M Of Securities From Time To Time
Benzinga · 6d ago
Cerus Affirms FY2026 Sales Guidance of $229.000M-$231.000M vs $248.850M Est
Benzinga · 6d ago
More
About CERS
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.

Webull offers Cerus Corp stock information, including NASDAQ: CERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CERS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CERS stock methods without spending real money on the virtual paper trading platform.